obviously I made many assumptions in projecting the value of K... probably none of them will be terribly accurate which in fact is the challenge with making valuations of any developmental stage biotech... in parts 1 & 2 I used a formula from biotech run-up... in part three I modeled from Celgene... I put this out just for fun... no one should take it too seriously... if nothing else it may spark some lively discussion around K...
I am long CTIX... quite optimistic about its future... very pleased with recent developments... and not particularly concerned about recent price movements in the stock... all of this is, of course, jmo...
News 
Market Data 
Discover 
AI
